ITW
62
4
CINF
51
4
BA
49
-3
WDC
43
2
AVGO
22
2
GPC
37
2
A
41
5
SJM
21
2
IPG
53
4
RHI
57
3
ROST
52
5
ILMN
37
5
PBI
65
5
DGX
50
2
GM
68
3
PDCO
38
3
LRCX
45
6
LEN
52
2
ETN
79
4
HAL
60
2
ITW
62
4
CINF
51
4
BA
49
-3
WDC
43
2
AVGO
22
2
GPC
37
2
A
41
5
SJM
21
2
IPG
53
4
RHI
57
3
ROST
52
5
ILMN
37
5
PBI
65
5
DGX
50
2
GM
68
3
PDCO
38
3
LRCX
45
6
LEN
52
2
ETN
79
4
HAL
60
2
Financhill
Back

Autolus Therapeutics PLC Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
51

AUTL
Autolus Therapeutics PLC

Last Price:
2.97
Seasonality Move:
0.84%

7 Day Trial

ALL ACCESS PASS

$ 7

Access The Stock Grader Trading Tool From "The King Of Quants"

More details here...

Autolus Therapeutics PLC Price Quote

$2.97
+0.13 (+4.58%)
(Updated: November 22, 2024 at 3:00 PM ET)

Autolus Therapeutics PLC Key Stats

Buy
51
Autolus Therapeutics PLC (AUTL) is a Buy
Day range:
$2.69 - $2.90
52-week range:
$2.69 - $7.45
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.58%
Volume:
3.4M
Avg. volume:
2.1M
1-year change:
-29.88%
Market cap:
$755.8M
Revenue:
$1.7M
EPS:
$-1.22

How Much Does Autolus Therapeutics PLC Make?

Data Unavailable

Is Autolus Therapeutics PLC Growing As A Company?

Data Unavailable

Autolus Therapeutics PLC Stock Price Performance

What Is Autolus Therapeutics PLC 52-Week High & Low?

Autolus Therapeutics PLC Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Autolus Therapeutics PLC?

Is Autolus Therapeutics PLC Cash Flow Positive?

  • What Is AUTL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$193.2M
  • What Is Autolus Therapeutics PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $559.6M
  • What Is Autolus Therapeutics PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$12.4M

Autolus Therapeutics PLC Return On Invested Capital

Data Unavailable

Autolus Therapeutics PLC Earnings Date & Stock Price

Autolus Therapeutics PLC Competitors

Autolus Therapeutics PLC Dividend Yield

Autolus Therapeutics PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -41.99%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 10.45
Upside from Last Price: 267.96%

Major Shareholders

  • How many AUTL shares are owned by institutional investors?
    211.5M AUTL shares are owned by institutional investors
  • How many AUTL shares are owned by insiders?
    0 AUTL shares are owned by insiders